{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:16Z","timestamp":1756339396673,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Giant cell arteritis (GCA) affects various ocular structures and potentially leads to vision loss. Traditional therapy involves a tapering regimen of high-dose systemic corticosteroids which are associated with adverse effects, including the risk of opportunistic infections such as toxoplasmosis from immune suppression. Tocilizumab, a humanised monoclonal antibody directed against the interleukin-6 receptor, offers an effective treatment option for GCA. In this report, we detail the successful treatment of GCA-associated, steroid-induced recurrent toxoplasma chorioretinitis (RTRC) using intravenous tocilizumab. A female patient in her 70s presented with GCA treatment challenges with prednisone, and subsequent complications of RTRC are discussed. 12 months after the initial presentation, the patient was treated with intravenous tocilizumab, leading to rapid resolution of the active lesion. At the 1-year follow-up, the patient maintained 20\/20 vision and showed no signs of inflammation or toxoplasmosis reactivation. This case suggests tocilizumab may be an effective alternative treatment for managing GCA, particularly in cases complicated by RTRC.<\/jats:p>","DOI":"10.1136\/bcr-2024-263369","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:20:24Z","timestamp":1740561624000},"page":"e263369","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Tolicizumab effectively controls giant cell arteritis and prevents recurrence of steroid-induced concomitant toxoplasmosis chorioretinitis"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-8567","authenticated-orcid":false,"given":"Anny M S","family":"Cheng","sequence":"first","affiliation":[{"name":"Ophthalmology, Florida International University Herbert Wertheim College of Medicine, Miami, Florida, USA"},{"name":"Specialty Retina Center, Deerfield Beach, Florida, USA"},{"name":"Ophthalmology, Broward Health, Fort Lauderdale, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailesh K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Specialty Retina Center, Deerfield Beach, Florida, USA"},{"name":"Ophthalmology, Broward Health, Fort Lauderdale, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa","family":"Abdelaziz","sequence":"additional","affiliation":[{"name":"Specialty Retina Center, Advanced Research LLC, Pompano Beach, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-9416","authenticated-orcid":false,"given":"Kakarla V","family":"Chalam","sequence":"additional","affiliation":[{"name":"Ophthalmology, Loma Linda University School of Medicine, Loma Linda, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"2025082701293637000_18.2.e263369.1","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00417-016-3434-7","article-title":"Giant cell arteritis: ophthalmic manifestations of a systemic disease","volume":"254","author":"De Smit","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2025082701293637000_18.2.e263369.2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/13543784.2021.1940949","article-title":"Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?","volume":"31","author":"Harkins","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"2025082701293637000_18.2.e263369.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008905","article-title":"Pathophysiology of ocular toxoplasmosis: Facts and open questions","volume":"14","author":"Greigert","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2025082701293637000_18.2.e263369.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010691","article-title":"Toxoplasmosis in patients with an autoimmune disease and immunosuppressive agents: A multicenter study and literature review","volume":"16","author":"Durieux","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025082701293637000_18.2.e263369.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.155861"},{"key":"2025082701293637000_18.2.e263369.6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102905","article-title":"New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation","volume":"11","author":"Greigert","year":"2022","journal-title":"J Clin Med"},{"key":"2025082701293637000_18.2.e263369.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222784"},{"key":"2025082701293637000_18.2.e263369.8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/09273948.2018.1499940","article-title":"Immune Mediators against Toxoplasma Gondii during Reactivation of Toxoplasmic Retinochoroiditis","volume":"27","author":"Rudzinski","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"2025082701293637000_18.2.e263369.9","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","article-title":"New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension","volume":"61","author":"Stone","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025082701293637000_18.2.e263369.10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fcimb.2019.00136","article-title":"Toxoplasma gondii: CD8 T Cells Cry for CD4 Help","volume":"9","author":"Khan","year":"2019","journal-title":"Front Cell Infect Microbiol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:29:44Z","timestamp":1756283384000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bcr-2024-263369"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263369","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}